Zhumadian Preschool Education College, Zhumadian, Henan Province 463000, China.
Gene. 2024 Sep 25;923:148566. doi: 10.1016/j.gene.2024.148566. Epub 2024 May 16.
Long non-coding RNAs have emerged as important players in cancer biology. Increasing evidence has uncovered their potency in improving cancer management as they can be used as a credible prognostic and diagnostic biomarker. Recently, DARS-AS1 has gained significant attention for its involvement in facilitating tumor progression. So far, numerous research has been reported its upregulation in different malignancies of human body systems and revealed its association with cancer hallmarks as well as clinicopathological characteristics. Importantly, targeting DARS-AS1 holds promise in cancer therapy. In the current study, we provide an in-depth analysis of its expression status and explore the underlying mechanisms through which DARS-AS1 contributes to tumor initiation, growth, invasion, and metastasis. Additionally, we examine the correlation between DARS-AS1 expression and clinicopathological features of cancer patients, shedding light on its potential as a cancer biomarker. Furthermore, we discuss the therapeutic potential of targeting DARS-AS1 in cancer treatment, highlighting emerging strategies, such as RNA interference and small molecule inhibitors. Boosting the understanding of its functional role can open new avenues for precision medicine, thus resulting in better outcomes for cancer patients.
长非编码 RNA 已成为癌症生物学中的重要参与者。越来越多的证据表明，它们可以作为一种可靠的预后和诊断生物标志物，在改善癌症管理方面具有潜力。最近，DARS-AS1 因其在促进肿瘤进展中的作用而受到广泛关注。迄今为止，已有大量研究报道其在人体不同系统的恶性肿瘤中的上调，并揭示了其与癌症标志和临床病理特征的关联。重要的是，靶向 DARS-AS1 在癌症治疗中具有广阔的前景。在本研究中，我们深入分析了其表达状态，并探讨了 DARS-AS1 促进肿瘤起始、生长、侵袭和转移的潜在机制。此外，我们还研究了 DARS-AS1 表达与癌症患者临床病理特征之间的相关性，探讨了其作为癌症生物标志物的潜力。此外，我们还讨论了靶向 DARS-AS1 在癌症治疗中的治疗潜力，强调了 RNA 干扰和小分子抑制剂等新兴策略。深入了解其功能作用可以为精准医学开辟新途径，从而为癌症患者带来更好的治疗效果。
